BrainsWay (BWAY) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Q3 2024 revenue reached $10.5 million, up 26% year-over-year, driven by strong global demand for Deep TMS systems and a steady 74% gross margin.
Operating profit was $300,000, compared to a $133,000 loss in Q3 2023; net income was $650,000, reversing a $230,000 loss.
Adjusted EBITDA for Q3 2024 was $1.1 million, up from $344,000 in Q3 2023.
Closed $20 million equity financing with Valor Equity Partners, enhancing resources for growth, R&D, and market expansion.
Shipped 177 Deep TMS systems in the first nine months of 2024, a 12% increase year-over-year.
Financial highlights
Q3 2024 revenue was $10.5 million, up from $8.3 million in Q3 2023.
Gross profit for Q3 2024 was $7.7 million with a 74% gross margin, consistent with the prior year.
Net income for the nine months ended September 30, 2024, was $1.4 million, reversing a $4.3 million loss in the prior year period.
Cash, cash equivalents, and short-term deposits totaled $48.4 million at quarter end, up $0.3 million from June 30, 2024.
Operating cash flow for Q3 2024 was $2.3 million, up from $1.4 million in Q3 2023.
Outlook and guidance
Full-year 2024 revenue guidance raised to $40–$41 million, representing 25%–29% growth over 2023.
Anticipates full-year operating income of 3%–4% and adjusted EBITDA of 10%–11%.
Expects continued positive cash flow and profitability for the full year.
Latest events from BrainsWay
- 27% revenue growth and 161% net income surge in 2025, with strong outlook for 2026.BWAY
Q4 202518 Mar 2026 - Q2 revenue up 28%, profitability sustained, and FDA expands Deep TMS use to age 86.BWAY
Q2 20242 Feb 2026 - Record revenue, profitability, and global expansion set stage for strong 2025 growth.BWAY
Q4 202426 Dec 2025 - Shelf registration enables up to $100M in flexible securities offerings to support growth and R&D.BWAY
Registration Filing16 Dec 2025 - Registration enables a major shareholder to resell up to 3.6 million ADSs, with potential dilution.BWAY
Registration Filing16 Dec 2025 - Strong growth, recurring revenue, and clinical innovation position the company for global expansion.BWAY
Investor Presentation2 Dec 2025 - Accelerated protocols, recurring revenue, and Deep TMS expansion drive breakout growth in 2026.BWAY
Analyst & Investor Day 20251 Dec 2025 - Q2 2025 revenue up 26% YoY, net profit $2M, and guidance raised on recurring growth.BWAY
Q2 202523 Nov 2025 - Q1 revenue up 27% with record profit growth, strong margins, and expanding clinical pipeline.BWAY
Q1 202521 Nov 2025